Recent

% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

commishfree1 4 posts  |  Last Activity: Aug 3, 2015 9:17 AM Member since: Jul 29, 2015
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    EBOLA News

    by rayludwiczak Jul 31, 2015 5:48 PM
    commishfree1 commishfree1 Aug 3, 2015 9:17 AM Flag

    Barnhizer last october-- "We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”

    OraSure doesn't seem to have any problem naming names.

  • Reply to

    EBOLA News

    by rayludwiczak Jul 31, 2015 5:48 PM
    commishfree1 commishfree1 Aug 3, 2015 8:54 AM Flag

    "The OraQuick(R) Rapid Ebola Antigen Test is an easy to use, rapid test, that we believe will be a critical tool in containing and controlling current outbreaks of the Ebola virus," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "We are grateful to the FDA for working closely with us throughout the EUA process to expedite deployment of our test."
    This project has been funded in whole or in part with Federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201500009C. OraSure has been awarded a contract for $1.8 million, with the potential of $10.4 million in total funding if all options are exercised from BARDA to advance clinical development of its rapid Ebola test. The Company continues to focus its efforts on securing sustainable product purchase commitments from both government and non-government sources.
    Critical reagents in the OraQuick(R) Ebola Rapid Antigen Test are being supplied by the Viral Hemorrhagic Fever Consortium and the Biological Defense Research Directorate at the United States Navy Medical Research Center (NMRC). The VHFC reagents were developed with the support of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health ("NIH/NIAID"). VHFC members, Autoimmune Technologies LLC, and Zalgen Labs LLC manufacture the critical reagents. "

    Here is another one with FDA emergency use authorization for you, Zag.

  • Reply to

    EBOLA News

    by rayludwiczak Jul 31, 2015 5:48 PM
    commishfree1 commishfree1 Aug 1, 2015 11:01 AM Flag

    "Buffered Charcoal Yeast Extract (BCYE) Agar is used for primary isolation and cultivation of Legionella pneumophila and other Legionella species from environmental samples and clinical specimens."

    Doesn't seem to be any ebola cases happening in the U.S. of A at present....but there is a legionnaires disease outbreak in New York City. Maybe the lads in Hubbard could whip up a batch of the above culture plates.

  • commishfree1 commishfree1 Jul 29, 2015 11:10 AM Flag

    July 28, 2015 /PRNewswire/ -- "Cepheid (CPHD) and FIND today unveiled the GeneXpert® Omni, the world's most portable molecular diagnostics system enabling unprecedented access to accurate, fast and potentially life-saving diagnosis for patients suspected of TB, HIV and Ebola in even the most remote areas of the world.
    At just 9 inches tall (about 23 cm) and weighing just 2.2 pounds (about 1kg), the GeneXpert Omni will run the same high quality PCR-based cartridge tests as Cepheid's existing family of GeneXpert Systems. Additionally, the GeneXpert Omni is battery-operated, wireless and web-enabled, setting a new standard in connectivity to transmit instrument and test information in real-time. The GeneXpert Omni is expected to substantially extend the reach of Cepheid's industry-leading technology platform, enabling true point-of-care testing for life-threatening conditions, including tuberculosis, drug-resistant tuberculosis, HIV and Ebola, to be conducted on demand at the patient's location.
    "For too long, access to best-in-class molecular diagnostics has been limited by the complexity of the tests and the systems that run them," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "With the GeneXpert Omni, global accessibility to molecular diagnostics is possible for the first time. The system's unprecedented portability means that it can literally go anywhere, and deliver critical diagnostic test results to support disease determination, treatment, and improved patient outcomes."

    This appears to be a game-changer in the field of molecular diagnostics.

ABT
50.51+0.01(+0.02%)Aug 4 4:02 PMEDT